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IntroductIon
The multi-subunit vacuolar-type H+-ATPase (V-ATPase) 
acidifies intracellular organelles, thereby controlling several 
events in the secretory and endocytic pathway, such as pro-
teolytic processing, protein degradation, autophagy, and gly-
cosylation. Structurally, it consists of a proton pore (V0 sector) 
and ATP hydrolysis domain (V1 sector), each composed of 
several core subunits (Forgac, 2007). In addition, there are two 
accessory subunits named ATP6AP1 and ATP6AP2.
ATP6AP1 has recently been shown to be the ortho-
logue of the yeast V-ATPase assembly factor Voa1 (Jansen 
et al., 2016a). Voa1 cooperates with four other chaperones 
(Vma21, Vma12, Vma22, and Pkr1) to assemble the V0 sec-
tor in the ER (Ryan et al., 2008). The newly assembled 
the biogenesis of the multi-subunit vacuolar-type H+-AtPase (V-AtPase) is initiated in the endoplasmic reticulum with the 
assembly of the proton pore V0, which is controlled by a group of assembly factors. Here, we identify two hemizygous missense 
mutations in the extracellular domain of the accessory V-AtPase subunit AtP6AP2 (also known as the [pro]renin receptor) 
responsible for a glycosylation disorder with liver disease, immunodeficiency, cutis laxa, and psychomotor impairment. We 
show that AtP6AP2 deficiency in the mouse liver caused hypoglycosylation of serum proteins and autophagy defects. the in-
troduction of one of the missense mutations into drosophila led to reduced survival and altered lipid metabolism. We further 
demonstrate that in the liver-like fat body, the autophagic dysregulation was associated with defects in lysosomal acidification 
and mammalian target of rapamycin (mtor) signaling. Finally, both AtP6AP2 mutations impaired protein stability and the 
interaction with AtP6AP1, a member of the V0 assembly complex. collectively, our data suggest that the missense mutations 
in AtP6AP2 lead to impaired V-AtPase assembly and subsequent defects in glycosylation and autophagy.
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Figure 1. AtP6AP2 mutations cause a novel glycosylation disorder. (a) Pedigrees and sequence profiles of ATP6AP2 mutations in families F1 and F2. 
Whole exome sequencing identified two mutations in three patients from two different families. Partial chromatograms show X-linked segregation for all 
patients. Family F1 shows on the left side the segregation of the de novo missense pathogenic mutation (c.293T>C) identified in patient P1 (F1-II.1), and 
on the right side the segregation of the maternally inherited SNP (c.268C>G) to patient P1 and healthy siblings (F1-II.2 and F1-II.3). Pedigree for family F2 
shows the segregation of the maternally inherited missense mutation (c.212G>A) to patient P2 (F2-II.1) and a healthy female sibling (F2-II.2). Patient P3 
(F2-III.1) inherited the same mutation as P2 from healthy individual F2-II.2. Black-filled squares indicate affected males, whereas black dots in white-filled 
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proton pore is then transported to the Golgi, where the 
preassembled V1 sector is added from the cytoplasm to con-
stitute a functional holoenzyme (Forgac, 2007). Mutations 
in ATP6AP1 lead to a congenital disorder of glycosylation 
(CDG), which is a rapidly growing disease group caused by 
the deficiency in components of the glycosylation machin-
eries and, more generally, in factors important for ER and 
Golgi homeostasis (Freeze et al., 2014; Scott et al., 2014; 
Hennet and Cabalzar, 2015). ATP6AP1 deficiency manifests 
with hypogammaglobulinemia as well as liver and cognitive 
abnormalities (Jansen et al., 2016a). Similar clinical pheno-
types occur in patients with mutations in either one of the 
two other putative orthologues of yeast assembly factors 
TMEM199 (Vma12) and CCDC115 (Vma22; Jansen et al., 
2016b,c), suggesting that V0 misassembly is the common 
pathogenic process in these syndromes.
The other accessory subunit ATP6AP2 has so far not 
been associated with CDG. In contrast, exon-skipping mu-
tations in ATP6AP2 have been associated with cognitive 
disorders with Parkinsonism, spasticity, epilepsy, and in-
tellectual disability (Ramser et al., 2005; Korvatska et al., 
2013). Functionally, the protein has been suggested to act 
as a (pro)renin receptor (Nguyen et al., 2002) and in several 
signaling pathways (Buechling et al., 2010; Cruciat et al., 
2010; Hermle et al., 2010, 2013; Schafer et al., 2015). The 
involvement of ATP6AP2 in V-ATPase function has been 
demonstrated in various cell culture and animal studies 
(Kinouchi et al., 2010, 2013; Riediger et al., 2011; Hermle 
et al., 2013; Trepiccione et al., 2016). In mice, the deletion 
of Atp6ap2 in cardiomyocytes, hepatocytes, or podocytes re-
sults in a significant decrease of V0 subunits and autophagy 
defects (Kinouchi et al., 2010, 2013; Kissing et al., 2017). 
Yet how ATP6AP2 mechanistically contributes to V-ATPase 
function remains to be determined.
Here, we identify missense mutations in ATP6AP2 
that cause a metabolic disorder with phenotypic similarity 
to the deficiency of other V0 assembly factors. Using com-
plementary in vitro and in vivo approaches, we show that 
ATP6AP2 interacts with members of the ER-based V0 as-
sembly complex. The interaction is impaired by the identified 
missense mutations in ATP6AP2, causing reduced V-ATPase 
activity, defective autophagy, and ultimately, compromised 
cellular and organismal homeostasis. Our results suggest that 
ATP6AP2 has a crucial role in V-ATPase assembly, both in 
invertebrates and vertebrates.
results
Mutations in X-linked AtP6AP2 cause immunodeficiency, 
liver disease, psychomotor impairment, and cutis laxa
Two hemizygous mutations in ATP6AP2 were identified 
by whole exome sequencing in three male individuals from 
two unrelated families included in cohorts of unsolved 
CDG cases. A Portuguese boy (P1) was shown to carry a 
hemizygous missense mutation c.293T>C (p.L98S) in exon 
3 (Fig. 1, a and b). The mutation was absent in the parents and 
the two brothers. In contrast, the neighboring polymorphism 
c.268C>G was transmitted by the heterozygous mother to all 
sons. Together, this suggested that p.L98S, which is evolutionary 
conserved between vertebrates and invertebrates, is a de novo 
mutation. Another hemizygous missense mutation, c.212G>A 
(p.R71H), was found in the same exon in two individuals (P2 
and P3) of a German family (Fig. 1, a and b). Both mutations 
were absent from more than 60,000 control individuals in the 
ExAC server (http ://exac .broadinstitute .org /).
The predominant symptoms of the patients are hepa-
topathy and immunodeficiency. For P1, ascites, collateral 
vascularization, and hepatosplenomegaly and increased 
liver transaminases aspartate transaminase (AST) and ala-
nine transaminase (ALT) led to a liver biopsy at 16 mo of 
age showing micronodular cirrhosis and steatosis (Table 1 
and Fig. 2, a and b). Recurrent infections initiated immu-
nological analysis that showed low levels of Igs, poor poly-
saccharide antibody response, decreased level of CD4+, 
and increased levels of CD8+ lymphocytes (Table 1). Treat-
ment with weekly subcutaneous Ig led to decreased infec-
tion frequency. P2 suffered from recurrent pulmonary and 
upper respiratory tract infections throughout infancy and 
childhood. Plasmaelectrophoresis revealed hypogamma-
globulinemia, and further investigation led to the diagnosis 
of IgG subclass deficiency with reduced IgG1 and IgG3. 
IgG substitution was consequently initiated, under which 
the patient’s general health status improved. Repeated ul-
trasounds showed hepatosplenomegaly with inhomoge-
neous and hyperechogenic structure. Serum cholesterol 
and the transaminase enzymes AST and ALT were mildly 
elevated (Table  1). P3 developed severe liver failure at 5 
mo of age. Liver biopsy revealed lipid accumulation and 
enlarged vacuolar structures within hepatocytes (Fig. 2, c 
and d). Similar to the other two patients, he has repeatedly 
suffered from infections, but his immunological status has 
so far been normal. Additional clinical features for all pa-
circles indicate healthy carrier females. The asterisk indicates the respective nucleotide change. (b) Schematic representation of the intron–exon structure 
of ATP6AP2 and the encoded protein. Numbers from 1–9 represent the different exons of the ATP6AP2 gene. The domain structure of the protein is sche-
matized underneath, and the numbers delimiting the different domains refer to amino acids positions. In white are depicted the signal peptide, the cleavage 
site, the transmembrane (TM) domain, and C-terminal ER retrieval motif. The green dotted lines indicate the positions of the missense mutations within 
the families, both at the nucleotide and the protein level (green boxes). The blue dotted lines indicate the position of the cytoplasmic domain. The conser-
vation of the affected amino acids is illustrated by the sequence alignments of the region containing the missense mutations (upper) and the cytoplasmic 
tail (lower) from Homo sapiens ATP6AP2 in Mus musculus, Xenopus laevis, and D. melanogaster, respectively. Although p.L98S is conserved in Drosophila, 
p.R71H is not. The ER retrieval motif is KxRxx in vertebrates and KKxx in Drosophila.
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tients were cutis laxa (P1, P2, and P3), dysmorphic features 
(P1 and P2), mild intellectual disability (P1 and P2), and 
mild ataxia (P2; Table 1).
Collectively, missense mutations in ATP6AP2 cause a 
new syndrome, predominantly affecting the liver, immune 
system, central nervous system, and skin connective tissue.
AtP6AP2 deficiency causes hypoglycosylation of serum 
proteins in patients and mice
Analysis of protein N-glycosylation showed that all patient 
sera had abnormal transferrin glycosylation profiles with 
decreased tetrasialotransferrin and increased tri-, di-, and 
monosialotransferrin (Fig. S1, a and b; and not depicted). 
Table 1. clinical data of patients with AtP6AP2 mutations
Parameter Patient 1 Patient 2 Patient 3
Sex Male Male Male
Current age 17 yr 21 yr 10 mo
Consanguinity None None None
Ethnicity Caucasian Caucasian Caucasian
Mutation cDNA c.293C>T c.212G>A c.212G>A
Mutation protein p.Leu98Ser (L98S) p. Arg71His (R71H) p. Arg71His (R71H)
Glycosylation defect IEF: tetrasialotransferrin: 34.2% (norm: 
48.5–65.3%); trisialotransferrin: 28.9% (norm: 
5.5–15.1%); disialotransferrin: 15% (norm: 
2.0–6.1%); monosialotransferrin: 3.3% (norm: 
0.0–3.7%); asialotransferrin: 1.5% (norm: 0%)
HPLC: tetrasialotransferrin 55.17% (norm: 
85.7–94.0%); trisialotransferrin 33.11% 
(norm: 1.16–6.36%); disialotransferrin 8.92% 
(norm: 0.38–1.82%); monosialotransferrin 
1.68% (norm: 0%)
HPLC: tetrasialotransferrin 35.7% (norm: 
85.7–94.0%); trisialotransferrin 36.4% (norm: 
1.16–6.36%); disialotransferrin 18.7% (norm: 
0.38–1.82%); monosialotransferrin 9.0% 
(norm: 0%)
Onset of symptoms 5 mo Directly after birth Directly after birth
Liver Prolonged neonatal jaundice and persistent 
hepatosplenomegaly with recurrent episodes 
of hypoalbuminemia and ascites
No hepatomegaly in childhood, but liver 
parenchyma of an inhomogeneous, 
hyperechoic structure.
Prolonged neonatal jaundice and 
hepatosplenomegaly. Cholestasis. Irregular 
liver parenchyma with portosystemic 
shunts and ascites. Hypoalbuminemia, 
hyperammonemia. Coagulopathy. Listed for 
liver transplantation.
Today: hepatomegaly, mild elevation of liver 
enzymes
Liver biopsy Micronodular hepatic cirrhosis with moderate 
macrovesicular steatosis (biopsy at 8 mo), 
elevated copper
Not available Diffuse micronodular hepatic cirrhosis
Elevated copper
Neonatal icterus + - +
Splenomegaly + + +
Infections Recurrent severe infections (e.g., sepsis, 
peritonitis)
Recurring pulmonary and upper respiratory tract 
infections throughout infancy and childhood
Recurring upper respiratory tract infections, 
positive blood cultures with pneumococcus at 
one occasion
Neurological symptoms Mild cognitive impairment Ataxic gait, mild cognitive impairment Normal
Cutis laxa Mild to moderate Pronounced, improvement over time Pronounced
Hypogammaglo-bulinemia + + -
IgG 2.31 g/L (reference: 5.6–13.8 g/L) Reduced IgG1 and IgG3 -
IgM <0.17 g/L 18 mg/dl (reference: 40–230 mg/dl) -
IgA <0.08 g/L <15 mg/dl (reference: 70–400 mg/dl) -
Increased transaminases At 17 yr, mild elevation of transaminases (AST 
61 U/l [reference: 15–46 UI/l], ALT 51 U/l 
[reference: 10–40 U/l])
Ranging from mild elevation at age 9 yr: AST 
92 U/l (reference: 8–60 U/l), ALT 59 U/l 
(reference: <44 U/l) to pronounced hepatic 
affection (AST 135 U/l)
Within the first year: AST 100–160 U/l, 
(reference: <71 U/l)
Serum copper Not available At 1 yr: 1.5 µmol/l (reference: 10–30 µmol/l) Normal serum copper at the age of 4 mo: 89 µg/
dl (reference: 65–165 µg/dl)
Normalized over the following months
Serum lipids At age 17 yr (liver normal): At age 20 yr: At age 5 mo:
Cholesterol: 172 (reference: 200 mg/dl) Cholesterol: 199 (reference: 200 mg/dl) Cholesterol: 254 (reference: 81–147 mg/dl)
LDL-cholesterol: 90 (reference: 50–130 md/dl) LDL-cholesterol: 149 (reference: 50–130 md/dl)
Other laboratory findings Low factor V and VI Low factor XI (58% [reference: >70%]) and free 
protein S (57.5% [reference: 60–140%])
Low factors II (27.7% [reference: 60–120%]), 
V (35.9% [reference: 55–130%]), VII (21.9% 
[reference: 47–130%]), IX (17.27% [reference: 
36–136%]), and XI (23.9% [reference: 
49–134%])
Factor V: 30% (reference: 65–148%), factor VII: 
24% (reference: 58–115%)
Other clinical findings Mild dysmorphic features Low-set ears, micrognathia, a flat and wide-set 
chest, laterally facing nipples, and hypospadia
IEF, isoelectric focusing.
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HPLC analysis confirmed that only half of the transferrin 
molecules (53.3% in patient 2 and 50.28% in P3) were pres-
ent as the correctly glycosylated tetrasialo-transferrin (Fig. 
S1, a and b). N-linked glycans on total plasma glycoproteins 
were analyzed using matrix-assisted laser desorption/ioniza-
tion time-of-flight (MAL DI-TOF) mass spectrometry (MS), 
which showed a relative increase in the undersialylated gly-
cans in patient 1 (Fig. 3 a).
So far, ATP6AP2 has not been implicated in any gly-
cosylation disorder. Moreover, analysis of protein glycosyla-
tion in a patient carrying one of the previously described 
exon-skipping variants in ATP6AP2 (Korvatska et al., 2013) 
showed a normal transferrin glycosylation profile and only a 
slight undersialylation of total serum proteins (Fig. S2, a and 
b). Therefore, we tested whether ATP6AP2 deficiency was 
sufficient to cause serum glycosylation abnormalities. Mice 
carrying a floxed allele of ATP6AP2 (Riediger et al., 2011) 
were injected with adeno-CRE (or adeno-GFP as a control) 
to induce an acute reduction of ATP6AP2 in the liver (Fig. S3 
a). Serum analysis showed elevation of the liver enzymes AST 
and ALT and high levels of cholesterol in the Cre-injected 
mice, suggesting liver damage and metabolic abnormalities 
(Fig. S3, b and c). MAL DI–TOF MS showed an increase of 
unsialylated and mono-sialylated N-glycans and a decrease in 
tri-sialylated N-glycans compared with adeno-GFP–injected 
mice (Fig. 3 b and Fig. S3 d). Thus, reduced ATP6AP2 ex-
pression in the liver is sufficient to recapitulate the glycosyla-
tion defects of the patients.
disease-associated mutations target 
AtP6AP2 for degradation
ATP6AP2 is a type I transmembrane protein that undergoes 
two proteolytic cleavages in the Golgi to generate a luminal 
or extracellular N-terminal fragment (NT) and a C-terminal 
fragment (CT) harboring a transmembrane domain and a 
short cytoplasmic tail (Fig. 1 b; Cousin et al., 2009; Nakagawa 
et al., 2017). The cytoplasmic tail contains an RxKxx ER re-
trieval motif that mediates retrograde transport to the ER 
(Nilsson et al., 1989; Schefe et al., 2006; Sihn et al., 2013). To 
investigate the effect of the missense mutations on expression 
and cleavage of ATP6AP2, we performed Western blotting 
in fibroblasts derived from patients P1 (ATP6AP2L98S) and 
P3 (ATP6AP2R71H). Steady-state levels of full-length (FL) 
ATP6AP2 were significantly reduced in ATP6AP2L98S but 
not ATP6AP2R71H fibroblasts, in comparison to ATP6AP2WT 
from two different healthy controls (Fig. 4, a and b). In con-
trast, mRNA levels of ATP6AP2R71H but not of ATP6AP2L98S 
were elevated (Fig.  4  d). Moreover, upon transient overex-
pression of HA-tagged ATP6AP2L98S and ATP6AP2R71H in 
HEK293T cells, the levels of both mutant proteins were de-
creased in comparison to the WT (Fig. 4, e and f). To under-
stand whether the reduced levels of the overexpressed mutants 
Figure 2. liver histology and fibroblasts of patients. Immunohistochemistry and transmission electron microscopy of liver tissue from patient 1 (P1) 
and patient 3 (P3). (a and b) Liver biopsy from P1 displays micronodular cirrhosis (a; Masson’s trichrome staining, 100×) and macro- and microvacuolar 
steatosis (b; Gordon and Sweet's staining, 200×). (c and d) Electron micrographs from single hepatocytes in liver biopsies from P3 with accumulations of 
autolysosomes (al; arrows) and lipid droplets (ld). Bars: (c) 5 µm; (d) 2 µm.
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were a result of decreased stability, we performed a cyclohex-
imide chase assay in HEK293T cells. Whereas ATP6AP2WT 
was still present after 18  h of cycloheximide pretreatment, 
ATP6AP2L98S and ATP6AP2R71H were barely detectable 
after 3 h, indicating that both mutant proteins have a shorter 
half-life and are targeted for degradation (Fig. 4, h–j).
Additionally, endogenous and overexpressed ATP6-
AP2L98S showed reduced levels of the cleavage products NT 
and CT (Fig. 4, a, c, e, and g), which suggested a defect in the 
export out of the ER. Therefore, we asked whether degra-
dation of this mutant involved the ER-associated degrada-
tion (ERAD) pathway, by which misfolded transmembrane 
proteins are targeted for proteasomal degradation via retro-
translocation into the cytoplasm. To inhibit ERAD, we coex-
pressed WT and dominant-negative versions of p97 (p97WT 
and p97QQ, respectively), a crucial component of the retro-
translocation machinery (Ye et al., 2001). Whereas p97QQ but 
not p97WT caused a significant accumulation of ATP6AP2L98S, 
ATP6AP2WT and ATP6AP2R71H steady-state levels were un-
changed (Fig. 4, k and l). Importantly, a version of ATP6AP2 
with mutations in the C-terminal ER retrieval motif 
(ATP6AP2QxQxx) not only was unaffected by both p97 con-
structs (Fig. 4, k and l) but also showed more cleavage (Fig. 4, 
e and g) and the longest half-life (Fig. 4, h–j). These findings 
were confirmed by localization studies of the different con-
structs in HeLa cells (Fig. S4, a and b). Whereas ATP6AP2WT 
and ATP6AP2R71H showed both ER and Golgi localization, 
ATP6AP2L98S localized primarily to the ER. ATP6AP2QxQxx 
showed an exclusive Golgi localization. Altogether, these re-
sults suggest that although the reduced retrograde transport 
of ATP6AP2QxQxx causes more protein stability, the increased 
ER localization of ATP6AP2L98S promotes its targeting for 
Figure 3. Hypoglycosylation of serum proteins in patient and mouse samples. (a) N-linked glycans of serum from a healthy individual (top) and 
from P1 with the L98S mutation in ATP6AP2 (bottom) were analyzed by MAL DI-TOF MS. (b) Representative MAL DI-TOF MS profiles of adeno-GFP- (n = 7) 
and adeno-CRE- (n = 5) injected mice (complete data can be found in Fig. S4). Red boxes and peaks in the lower panels of a and b indicate the increase of 
biantennary glycans (compared with most extensively branched N-glycans in the control), which also contain less undersialylated structures.
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Figure 4. AtP6AP2 mutants p.l98s and p.r71H are degraded via erAd. (a) Endogenous levels of ATP6AP2 FL and NT in control and patient fibroblasts 
using anti-ATP6AP2-NT. The asterisk * indicates glycosylated form of ATP6AP2L98S. (b and c) Expression levels of ATP6AP2 FL and NT relative to those of 
β-actin were calculated. All data are mean ± SEM of three independent experiments. ns, not significant; *, P < 0.05; **, P < 0.01. The statistical significance 
was determined by an unpaired Student’s t test. (d) ATP6AP2 mRNA quantification in control and patient fibroblasts. All data are mean ± SEM of three 
independent experiments. ns, not significant; *, P < 0.05. The statistical significance was determined by an unpaired Student’s t test. (e) Steady-state levels 
of overexpressed ATP6AP2WT-HA, ATP6AP2L98S-HA, ATP6AP2R71H-HA, and ATP6AP2QxQxx-HA at 48 h after transfection in HEK293T cells. Anti-HA reveals FL and 
CT. The asterisk indicates glycosylated form of ATP6AP2L98S. (f and g) Expression levels of ATP6AP2 FL and CT relative to those of β-actin were calculated. All 
data are mean ± SEM of five independent experiments. ns, not significant; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. The statistical significance was deter-
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ERAD. For ATP6AP2R71H, which showed higher endog-
enous steady-state levels and more Golgi localization than 
ATP6AP2L98S, the precise degradation pathway remains unclear.
AtP6AP2l98s is posttranslationally 
modified by n-glycan addition
Apart from lower expression levels, overexpressed ATP6-
AP2L98S in HEK293T cells and endogenous ATP6AP2L98S in 
patient fibroblasts also exhibited an additional slower migrat-
ing band in immunoblots (Fig. 4, a and e; and Fig. 5, a and b). 
As the majority of proteins synthesized in the ER undergo 
glycosylation, we tested whether this band was the result 
of glycan addition. For this, we treated protein lysates with 
different deglycosylation enzymes. Whereas O-glycosidase 
and sialidase A treatment did not affect the mobility of the 
upper band, addition of the N-glycosidases endoglycosidase 
H (Endo H) and peptide-N-glycosidase F (PNGase F) com-
pletely eliminated it (Fig. 5, a and b), suggesting that a fraction 
of ATP6AP2L98S is N-glycosylated and localized in the ER.
N-glycosylation in the ER typically occurs cotransla-
tionally through oligosaccharyltransferases complexes harbor-
ing the STT3A subunit (Cherepanova et al., 2016). However, 
when glycosylation sites are skipped or when proteins are 
misfolded, N-glycans can also be added posttranslationally by 
STT3B-containing oligosaccharyltransferase complexes (Sato 
et al., 2012; Cherepanova et al., 2016). To investigate whether 
the N-glycan addition in ATP6AP2L98S occurred co- or 
posttranslationally, we expressed ATP6AP2L98S in STT3A 
and STT3B KO cells (Cherepanova and Gilmore, 2016). 
We found that the slower migrating band ATP6AP2L98S was 
present in STT3A but not in STT3B KO cells (Fig.  5  d), 
suggesting that ATP6AP2L98S is subject to posttranslational 
N-glycosylation in the ER. Given that this mutant protein 
is targeted for ERAD, the results suggest that the N-glycan is 
added as a result of misfolding.
the p.l98s mutation causes developmental defects and 
decreased protein stability in drosophila
To better understand the consequences of the p.L98S muta-
tion on animal development and homeostasis, we turned to 
Drosophila, where the leucine residue at position 98 is con-
served (Fig. 1 b). Null alleles of the Drosophila orthologue 
of ATP6AP2 (also known as VhaM8.9 or VhaPRR) are early 
lethal (Hermle et al., 2013). Thus, we generated an ATP6AP2 
transgene carrying the p.L98S mutation and used a genetic 
rescue approach in which we expressed ATP6AP2L98S mutant 
under the ATP6AP2 promoter and in the background of the 
ATP6AP2Δ1 null allele (hereafter referred to as ATP6AP2L98S; 
see Table S1 for precise genotypes; Hermle et al., 2013). 
In parallel, we analyzed versions of WT ATP6AP2 with 
and without a C-terminal Myc tag (ATP6AP2WT-Myc and 
ATP6AP2WT, respectively), a deletion of the ER retrieval 
motif (ATP6AP2ΔKKxx), and a mutant of the furin cleavage site 
(ATP6AP2AxxA) to assess the importance of ATP6AP2 pro-
teolytic cleavage in the function of ATP6AP2. Expression of 
ATP6AP2WT and ATP6AP2AxxA led to full restoration of via-
bility into adulthood (Fig. 6, a and b). In contrast, ATP6AP2L98S 
mildly impaired larval-to-pupal transition (Fig. 6 a), and both 
ATP6AP2L98S and ATP6AP2ΔKKxx significantly reduced the 
percentage of adults eclosing from the pupal case (Fig. 6 b). 
These adult survivors demonstrated poor mobility, decreased 
or absent climbing capabilities, blistered wings, and reduced 
head size and died 3–4 d after eclosion (not depicted).
Next, we analyzed ATP6AP2 protein expression and 
processing by Western blotting in whole larval extracts. Com-
pared with endogenous ATP6AP2, ATP6AP2WT-Myc showed 
reduced levels of FL protein and similar levels of cleaved NT. 
In ATP6AP2ΔKKxx larvae, FL and NT levels were higher com-
pared with endogenous control (Fig. 6, c and d), indicating 
enhanced cleavage and stability of the protein as found for 
ATP6AP2QxQxx overexpression in HEK293T cells. As ex-
pected, proteolytic cleavage was suppressed in ATP6AP2AxxA 
with a concomitant increase of the FL protein. Importantly, 
in ATP6AP2L98S larvae, the levels of both FL and NT were 
reduced compared with WT controls in whole larval lysates 
(Fig. 6, c and d), confirming the decreased stability observed 
for the mutant proteins in patient fibroblasts and HEK293T 
cells. Although glycosylated forms of ATP6AP2L98S were not 
seen when expressed under its own promoter (Fig. 6, c and e), 
ATP6AP2L98S was also N-glycosylated in Drosophila upon 
overexpression with the UAS-Gal4 system (Fig. 5 c). Collec-
tively, the p.L98S mutation in Drosophila impairs ATP6AP2 
protein stability and is sufficient to cause developmental defects.
Flies with the p.l98s mutation present brain developmental 
defects and impaired lipid homeostasis
To understand the cause of the compromised viability of the 
ATP6AP2L98S flies, we turned to two tissues affected in the pa-
tients: the central nervous system and the fat body, a liver-like 
tissue. We first examined whether differences in expression 
mined by an unpaired Student’s t test. (h–j) Turnover of ATP6AP2 WT, L98S, R71H, and QxQxx was determined by cycloheximide (100 µM) chase experiments. 
The chase started 24 h after transfection and was allowed for the indicated time. The percentage of the protein decay was graphically reported (i), and 
the difference of the in cellulo half-life between the WT, L98S, R71H, and QxQxx was analyzed in j. Blots are representative of four individual experiments. 
All data are mean ± SEM of four independent experiments. ns, not significant; **, P < 0.01; ***, P < 0.001. The statistical significance was determined by a 
regular two-way ANO VA followed by a Bonferroni multiple comparisons test in i and an unpaired Student’s t test in j. (k) HEK293T cells were transiently 
cotransfected with the CT-tagged construct ATP6AP2 WT, L98S, R71H, and QxQxx and p97-WT-His or p97-QQ-His. Samples were analyzed with anti-HA and 
anti-His antibodies. (l) Expression levels of ATP6AP2 FL in the presence of p97WT or p97QQ relative to those of β-actin were calculated. All data are mean ± 
SEM of three independent experiments. ns, not significant; *, P < 0.05. The statistical significance was determined by an unpaired Student’s t test. Molecular 
mass is indicated in kilodaltons.
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levels and processing could be observed for ATP6AP2 in 
these tissues. We found that FL endogenous ATP6AP2 and 
FL transgenic ATP6AP2WT were similarly expressed in whole 
larval extracts, fat body, and larval brain (Fig. 6 e). In contrast, 
FL ATP6AP2L98S expression was highly reduced, especially in 
fat body tissue. Furthermore, minimal cleavage of ATP6AP2 
was observed in fat body for both endogenous and transgenic 
constructs, which could indicate a higher need for the FL 
form of ATP6AP2 in the fat body (Fig. 6 e).
To assess the consequences of the p.L98S mutation in 
central nervous system development, we examined the de-
veloping brain in ATP6AP2L98S third instar larvae. Using im-
munolabeling, we found that the p.L98S mutation strongly 
affected the optic lobes, which are one of the major structures 
of the Drosophila brain (Fig. 6, f and g). The optic lobes de-
velop from neuroepithelial cells, which first increase in num-
ber through symmetric divisions and are later converted into 
optic lobe neuroblasts (Yasugi et al., 2008; Egger et al., 2010). 
These neuroblasts divide asymmetrically to self-renew and to 
generate neurons. We observed that in ATP6AP2L98S brains 
there is an expansion of optic lobe neuroblasts, marked by the 
expression of Deadpan (Dpn; Fig. 6 g). Whereas in WT mid 
third instar larval brains, only three to four cell rows of optic 
lobe neuroblasts could be observed, in ATP6AP2L98S mutant 
Figure 5. the mutant AtP6AP2l98s migrates as a double band as a result of posttranslational n-glycosylation. (a) HEK293T cells were transiently 
transfected with C-terminally HA-tagged constructs of WT and L98S. Protein extracts were immunoblotted with anti-HA antibody after incubation with (+) 
and without (-) Endo H, O-glycosidase, PNGase F, or sialidase A. Asterisk indicates slower migrating band for ATP6AP2L98S. (b) The expression of endogenous 
ATP6AP2 was analyzed in two different control fibroblasts from healthy donors and fibroblasts from P1 (p.L98S) and P3 (p.R71H). Cell lysates were separated 
by SDS-PAGE after incubation with (+) or without (-) Endo H, O-glycosidase, or PNGase F, and the proteins were revealed with anti-ATP6AP2-NT antibody. 
(c) ATP6AP2WT and ATP6AP2L98S were overexpressed with patched(ptc)-GAL4 in flies, and lysates were analyzed by immunoblot with anti-ATP6AP2-NT 
antibody after incubation with (+) and without (-) Endo H, O-glycosidase, or PNGase F. (d) Parental HEK293, STT3A KO, and STT3B KO cells were transiently 
transfected with ATP6AP2WT or ATP6AP2L98S. Cell lysates were analyzed by immunoblotting and revealed with anti-HA antibody. β-Actin served as a loading 
control. Data in a–d are representative of three, three, two, and five experiments, respectively. Molecular mass is indicated in kilodaltons.
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Figure 6. l98s mutation causes decreased viability and premature differentiation of neural progenitors in drosophila. (a) Percentage of pupari-
ation of the different ATP6AP2 mutants used in this study. (b) Percentage of eclosion of adult flies. All data are mean ± SEM of three to five independent 
experiments (50–100 animals per genotype per experiment). *, P < 0.05; ****, P < 0.0001. Significance was determined by one-way ANO VA followed by 
a Bonferroni multiple comparisons test. (c) Western blot of ATP6AP2 in whole larvae extracts from WT and rescued flies showing expression levels and 
cleavage pattern of endogenous ATP6AP2 and the different rescue transgenes. α-Tubulin is used as loading control. (d) Relative levels of FL (left) and NT 
(right) ATP6AP2 mutants compared with endogenous ATP6AP2. All data are mean ± SEM of seven independent experiments (5 animals per genotype per 
experiment). ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. The statistical significance was determined by a paired Student’s t test. (e) Western blot 
of ATP6AP2 in whole larvae, fat body, and brain extracts of WT, ATP6AP2L98S, and ATP6AP2WT rescue flies. β-Actin is used as loading control. Blot is represen-
tative of four independent experiments (5, 15, and 50 animals per genotype per experiment [larval, fat body, and brain extracts, respectively]). (f) Schematic 
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brains, most of the optic lobe was occupied by Dpn-positive 
cells, indicating a premature conversion to neuroblasts possi-
bly at the expense of neuroepithelial cells. Consistent with a 
premature and increased neurogenesis, we found an increase 
in cells positive for the pan-neuronal marker ELAV in the 
optic lobes and the central brain of mid and late third instar 
ATP6AP2L98S larvae (Fig. 6 g). These observations suggest that 
ATP6AP2 plays an important role in Drosophila neural devel-
opment, which is altered by the patient’s missense mutation.
The larval fat body is featured by a high amount of 
lipid droplets, which are storage organelles for triglycerides 
(TAGs) and cholesteryl esters (Ugur et al., 2016). Compared 
with WT, we found an increase in the size of lipid droplets in 
ATP6AP2L98S mutant fat body cells (Fig. 7, a and b) as well 
as an increase in the number of small and large lipid drop-
lets with a concomitant decrease of medium-sized droplets 
(Fig. 7 c). The increase in lipid droplets was accompanied by 
an increase in the levels of total TAGs in ATP6AP2L98S mutant 
larvae (Fig. 7 d). An increase in TAGs was also observed in 
ATP6AP2ΔKKxx but not in ATP6AP2AxxA or ATP6AP2WT-Myc 
animals. Furthermore, in clones expressing ATP6AP2L98S 
in the null background, we found a strong increase in lipid 
droplet size compared with the surrounding ATP6AP2WT-Myc 
tissue (Fig.  7  e, and see Table S1 for precise genotype). A 
similar phenotype was seen in clonal populations of cells in 
which ATP6AP2 was down-regulated using RNAi (Fig. 7 f), 
suggesting that ATP6AP2L98S is a loss-of-function mutation. 
Furthermore, RNAi-mediated knockdown of ATP6AP2 also 
provoked lipid droplet accumulation in other tissues, such as 
Malpighian tubules (Fig. 7 g) and pupal wings (see Fig. 9 h).
Finally, we tested whether the down-regulation of other 
V-ATPase–associated genes could cause the same phenotype. 
Indeed, we found increased lipid droplet size in fat body and 
Malpighian tubules upon knockdown of ATP6V1C1 and 
ATP6AP1 (also known as Vha44 and VhaAC45, respectively; 
Fig. 7, f and g), suggesting that lipid accumulation in ATP6A-
P2L98S cells is a general V-ATPase–dependent phenotype.
AtP6AP2 forms a complex with other 
V-AtPase assembly factors
Given the phenotypic overlap between the ATP6AP2L98S mu-
tant and ATP6V1C1 and ATP6AP1 knockdown in flies, we 
analyzed whether ATP6AP2 could interact with V-ATPase 
subunits and assembly factors and, if yes, whether the mis-
sense mutations could affect these interactions. We performed 
affinity purification coupled to MS (AP-MS) in HEK293T 
cells transiently overexpressing ATP6AP2WT. Among the 
top-ranking interactors, we found assembly factors for the V0 
sector of the V-ATPase (ATP6AP1, VMA21, and TMEM199) 
and V0 subunits themselves (ATP6V0A2 and ATP6V0D1; 
Fig.  8  a), three of which have been implicated in CDG 
(ATP6AP1, TMEM199, and ATP6V0A2; Kornak et al., 2008; 
Jansen et al., 2016a,c). For the top candidates ATP6AP1 and 
VMA21, the interaction was confirmed by coimmunoprecip-
itation (coIP) of overexpressed tagged proteins in HEK293T 
cells (Fig. 8 b), and for ATP6AP1 also by endogenous coIP 
(Fig. 8 c). Moreover, in a yeast two-hybrid (Y2H) screen on 
a mouse cDNA library, we found ATP6AP1 as a binding 
partner of ATP6AP2. Mapping experiments with different 
truncated constructs suggested that the interaction requires 
the N-terminal luminal domains of both proteins, which in 
the case of ATP6AP2 harbors both amino acids mutated in 
our patients. Accordingly, both mutations impaired the in-
teraction with ATP6AP1 in Y2H (Fig. S5) and in reciprocal 
coIP experiments (Fig. 8, d and e). In contrast, a construct 
with a deletion of exon 4 mimicking the effect of the ex-
on-skipping mutation in P4 bound with similar strength to 
ATP6AP1 as ATP6AP2WT (Fig. S2 c). Together, these results 
suggest that ATP6AP2 forms a complex with other V-ATPase 
assembly factors, and that this interaction is impaired by the 
CDG-associated missense mutations.
AtP6AP2 mutations leads to defects in autophagy
To address the functional consequences of the decreased 
interactions with V-ATPase assembly factors, we analyzed 
V-ATPase activity in ATP6AP2L98S fat body cells by staining 
with the acidotropic dye Lysotracker. ATP6AP2L98S mutant 
clones showed a reduction in Lysotracker-positive organ-
elles compared with the WT surrounding tissue, indicating 
reduced acidity (Fig. 9 a). In accordance with the importance 
of V-ATPase–mediated acidification for autophagic degrada-
tion (Mauvezin et al., 2015), we found a correlation between 
lipid droplet size increase in knockdown cells and impaired 
lysosomal activity as determined using the GFP-LAMP re-
porter that accumulates when lysosome function is im-
paired (Fig.  9  b; Pulipparacharuvil et al., 2005). Moreover, 
we observed an accumulation of the autophagosomal marker 
Atg8a-mCherry (LC3 in mammals) in fat body cells express-
ing ATP6AP2 RNAi (Fig. 9 c) as well as an increase of en-
dogenous Atg8a in ATP6AP2L98S clones in fat body (Fig. 9 d).
To further characterize the autophagy defect, we ana-
lyzed the processing of Atg8a by Western blotting. Atg8a can 
be visualized as one or two forms: a nonprocessed cytosolic 
form (Atg8a-I) and a faster migrating membrane-associated 
lipidated form (Atg8a-II), which is the active form involved 
in autophagosome formation. We detected an increase in 
representation of the larval Drosophila brain. CB, central brain; OL, optic lobe. (g) Representative micrographs (out of three independent experiments; 5–10 
brains per genotype per experiment) for WT and ATP6AP2L98S brain lobes from early (top) mid (middle) and late (bottom) third instar (third) larvae stained 
with the pan-neuronal marker ELAV (red in the merged panels) and the neuroblasts marker Deadpan (Dpn, green in the merged panels). Bar, 50 µm. Dashed 
lines in the merged panel separate the optic lobe (left) from the central brain (right). The region occupied by optic lobe neuroblasts is indicated with lines in 
mid and late third instar larvae. Molecular mass is indicated in kilodaltons.
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Figure 7. l98s mutation in drosophila 
AtP6AP2 causes impaired lipid metabolism. 
(a) Bodipy (green) staining of wandering third 
instar larval fat bodies of WT and ATP6AP2L98S 
rescue. (b) Quantification of lipid droplet size 
in WT and ATP6AP2L98S third instar larval fat 
bodies. Each dot represents one lipid droplet. 
Data are from four independent experiments 
(5–10 animals per genotype per experiment) 
in which a total of 28 and 34 fat bodies were 
analyzed for WT and ATP6AP2L98S, respectively. 
****, P < 0.0001. Significance was determined 
by a Kolmogorov-Smirnov test. (c) Binning 
of data from (b) showing the distribution of 
lipid droplets by size category (small, me-
dium, large). (d) Total TAG levels assayed en-
zymatically in WT, ATP6AP2WT-Myc, ATP6AP2L98S, 
ATP6AP2ΔKKxx, and ATP6AP2AxxA wandering 
third instar larvae. Lines represent the mean ± 
SD of 5–10 independent experiments (5 ani-
mals per genotype per experiment). ns, not 
significant; ***, P = 0.0001; ****, P < 0.0001. 
Significance was determined by one-way 
ANO VA followed by a Bonferroni multiple 
comparisons test. (e) Analysis of lipid droplets 
in clonal populations of fat body cells express-
ing ATP6AP2L98S (RFP-negative) surrounded 
by ATP6AP2WT-Myc cells (RFP-positive). Lipid 
droplets stained with Bodipy (green). DNA 
stained with Hoechst (blue). (f) Analysis of 
lipid droplets (green) in clonal populations of 
fat body cells and expressing RNAi against AT-
P6AP2, ATP6V1C1, and ATP6AP1 (RFP-positive) 
surrounded by WT cells (RFP-negative). 
(g) Analysis of lipid droplets (green) in clonal 
populations of Malpighian tubule cells ex-
pressing RNAi against ATP6AP2, ATP6V1C1, 
and ATP6AP1 (RFP-positive) surrounded by WT 
cells (RFP-negative). Right panels are magnifi-
cations of the insets demarked in left panels. 
(a and e–g) Bars, 50 µm. Micrographs of clonal 
analyses are representative of at least three 
independent experiments (10–15 animals per 
genotype per experiment).
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Atg8a-II in ATP6AP2L98S larval lysates compared with WT 
and ATP6AP2WT-Myc (Fig.  9  e). To distinguish between in-
creased autophagosome formation or decreased autophagic 
degradation (or a combination of both), we tested the lev-
els of Ref(2)p (p62 in mammals). Consistent with de-
creased autophagic degradation, Ref(2)p was increased in 
ATP6AP2L98S clones (Fig. 9 d) and ATP6AP2L98S whole larval 
lysates (Fig. 9 e). Importantly, this is in agreement with the 
increased LC3-II, p62, and LAMP1/2 levels in mouse liver 
tissue acutely depleted of ATP6AP2 (Fig. S3 a; Kissing et al., 
Figure 8. AtP6AP2 interacts with V-AtPase assembly factors. (a) Table showing the list of top-ranking interactors of ATP6AP2 based on two differ-
ent score systems (CompPASS and MiST; Jäger et al., 2011). (b) CoIPs in HEK293T cells using the indicated constructs. Proteins were immunoprecipitated 
with anti-Myc antibody, and cell lysates were subjected to immunoblotting with anti-HA and anti-Myc antibodies. (c) Endogenous immunoprecipitation 
of ATP6AP2 in HEK293T cells using anti-ATP6AP2 (NT) antibody or control IgG. Immunoprecipitates were analyzed with anti-ATP6AP2 and anti-ATP6AP1. 
Lysate inputs of both proteins are on the left. The asterisks indicate heavy and light chains of the antibodies. (d) CoIPs in HEK293T cells using the indicated 
constructs. Proteins were immunoprecipitated with anti-Myc antibody, and cell lysates were subjected to immunoblotting with anti-HA and anti-Myc 
antibodies. (e) Reciprocal coIP experiment using anti-HA antibodies for immunoprecipitation. Toca-1-Myc is a negative control. Data are representative of 
eight (b), three (c), five (d), and two (e) independent experiments. Molecular mass is indicated in kilodaltons.
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Figure 9. AtP6AP2 knockdown and AtP6AP2l98s mutation lead to lipid accumulation as a result of autophagic defects. (a) Lysotracker labeling 
(green in merged panel) of ATP6AP2L98S clonal populations (RFP-negative) of fat body cells surrounded by ATP6AP2WT-Myc cells (RFP-positive). Bar, 50 µm. 
(b) GFP-LAMP accumulation (red in merged panel) and increased lipid droplet size in ATP6AP2 knockdown cells (RFP-positive, blue in merged panel). Lipid 
droplets stained with Bodipy (green in merged panel). Bar, 50 µm. (c) Atg8a-mCherry accumulation (red in merged panel) in ATP6AP2 knockdown cells 
(GFP-positive, green in merged panel). Bar, 50 µm. (d) Endogenous Atg8a (upper) and Ref(2)P (lower) staining (green in merged panel) in ATP6AP2L98S clonal 
populations (RFP-negative) of fat body cells surrounded by ATP6AP2WT-Myc cells (RFP-positive). Bars, 20 µm. (e) Western blot of Ref(2)P and Atg8a in whole 
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2017). Finally, we found an increase of Atg8a–II and Ref(2)
p in ATP6AP2ΔKKxx, but not in ATP6AP2AxxA larval lysates 
(Fig.  9  e), suggesting that ER retrieval but not cleavage is 
essential for ATP6AP2 function in autophagy.
The V-ATPase has also been involved in the activa-
tion of mammalian target of rapamycin (mTOR) signaling 
(Zoncu et al., 2011), which conversely triggers autophagy 
when inhibited (Noda and Ohsumi, 1998). Thus, to ana-
lyze whether the ATP6AP2L98S mutant could alter mTOR 
activity, we tested the phosphorylation status of 4E-BP, an 
important downstream effector of mTOR. Fat body clones 
expressing ATP6AP2L98S showed reduced levels of phos-
pho-4E-BP (p4E-BP) compared with the surrounding 
ATP6AP2WT-Myc tissue (Fig.  9  f). Likewise, p4E-BP was 
reduced in Western blotting of fed, starved, and refed 
ATP6AP2L98 whole larvae compared with control animals 
(Fig. 9 g), suggesting that stimulation of autophagy cause by 
mTOR inactivation in cells where lysosomal degradation is 
defective could contribute to the pathology. These findings 
were supported by transmission electron microscopy studies 
performed in pupal wings, in which knockdown cells showed 
a strong accumulation of lipid droplets and other organelles 
in large electron-dense vacuoles (Fig.  9  h). These vacuoles 
most likely represent autolysosomes with reduced degradative 
capacity and are reminiscent of the vacuoles found in the liver 
biopsy of P3 (Fig. 2 d).
Collectively, these results suggest that defects in 
V-ATPase activity, autophagy, and mTOR signaling are key 
to the disease caused by ATP6AP2 missense mutations, par-
ticularly with regard to the steatohepatitis.
dIscussIon
Genetic diseases caused by defective V-ATPase function are 
clinically diverse. Mutations in the core subunits ATP6V1B1 
and ATP6V0A4 manifest in cells specialized in proton se-
cretion such as renal intercalated cells and osteoclasts where 
these subunits are highly expressed (Forgac, 2007). In contrast, 
mutations in ubiquitously expressed core subunits and V0 as-
sembly factors give rise to more systemic disorders (Kornak 
et al., 2008; Kortüm et al., 2015; Jansen et al., 2016a,b,c; Van 
Damme et al., 2017). The clinical similarity of ATP6AP2 de-
ficiency with mutations in other assembly factors, most nota-
bly ATP6AP1, strongly argues for a role of ATP6AP2 in the 
assembly of the V0 sector of the V-ATPase. In support of this 
hypothesis, we show that ATP6AP2 not only interacts with 
V0 assembly factors but also requires retrograde delivery to 
the ER for function as has previously been shown for several 
yeast assembly factors (Malkus et al., 2004; Ryan et al., 2008; 
Jansen et al., 2016a). Moreover, the identified missense mu-
tations impair the interaction with ATP6AP1 and can cause 
reduced proton pump activity.
The acute depletion of ATP6AP2 in the mouse liver 
was sufficient to recapitulate the glycosylation and autoph-
agy defects of the patients. Mechanistically, both direct and 
indirect effects on the glycosylation machinery are possible 
in the absence of V-ATPase activity. Whereas some glycosyla-
tion enzymes like sialidases require low pH for optimal activ-
ity (al-Awqati et al., 1992), defects in V-ATPase assembly or 
function could also cause secondary defects in ER and Golgi 
homeostasis that are responsible for the glycosylation defects. 
Thus, it remains to be determined how ATP6AP2 deficiency 
affects glycosylation and how far the glycosylation defect 
contributes to the clinical symptoms.
The observed defect in autophagic flux can, on the 
other hand, more easily be linked to V-ATPase dysfunction 
and to the clinical phenotype. As V-ATPase–mediated acid-
ification is generally indispensable for the final degradation 
step in autophagy, it can be argued that a ubiquitous small 
decrease in V-ATPase activity primarily manifests in organs 
with a high need for autophagy. Whereas plasma cells of the 
immune system depend on high rates of autophagy to coun-
teract ER expansion when Ig synthesis is high (Pengo et al., 
2013), dysfunctional lipophagy can cause steatosis of the liver 
(Singh et al., 2009; Baiceanu et al., 2016). The latter process 
was recapitulated in the Drosophila mutant, where fat body 
cells showed lipid accumulation along with reduced organel-
lar acidity and decreased lysosomal degradation. Aggravating 
the pathology, the decreased mTORC1 activation, observed 
in these cells, may permit an inappropriate induction of au-
tophagosome formation, autophagosome maturation, and 
fusion with lysosomes despite the inability to execute deg-
radation in the final step of autophagy (Ramachandran et al., 
2013; Mauvezin et al., 2015). Such a block in autophagy flux 
after its induction is supported by the observed lipidation of 
LC3/Atg8a and p62/Ref(2)P accumulation and may explain 
the enlarged autolysosomes seen in the liver biopsies and in 
the epithelial cells of the fly wings.
Whether the intellectual disability and mild ataxia in 
patients with ATP6AP2 missense mutations are also a con-
sequence of reduced autophagy awaits further testing. By 
larvae extracts of WT and ATP6AP2WT-Myc, ATP6AP2L98S, ATP6AP2AxxA, and ATP6AP2ΔKKxx flies. β-Actin is used as loading control. Blot is representative of five 
independent experiments (five animals per genotype per experiment). (f) p-4E-BP staining of ATP6AP2L98S clonal populations (RFP-negative) of fat body cells 
surrounded by ATP6AP2WT-Myc cells (RFP-positive). Bar, 50 µm. (g) Western blot of p4E-BP in fat body extracts of WT and ATP6AP2L98S third instar larvae in fed 
(F), starved (S), and refed (RF) conditions. α-Tubulin is used as loading control. Blot is representative of four independent experiments (20–25 animals per 
genotype per experiment). (h) EM micrographs of pupal wings in which ATP6AP2 has been down-regulated in the dorsal compartment using RNAi driven 
by apterous-Gal4. As opposed to WT cells from the ventral epithelium (left), knockdown cells (right) show accumulation of lipid droplets (ld) and other 
organelles in large autolysosomes (al). Bar, 200 nm. Micrographs of clonal analyses are representative of at least three independent experiments (10–15 
animals per genotype per experiment). Molecular mass is indicated in kilodaltons.
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removing dysfunctional organelles and macromolecules, 
autophagy is beyond dispute an important survival mecha-
nism in postmitotic neurons (Hara et al., 2006; Mariño et 
al., 2011). Accordingly, the neuron-specific down-regulation 
of ATP6AP2 in Drosophila and mouse has been shown to 
lead to autophagy defects and cognitive impairment (Dubos 
et al., 2015). However, the premature neuronal differentiation 
phenotype in the developing ATP6AP2L98S fly brains argues 
for additional defects in signaling pathways involved in neu-
ral development. One candidate pathway is Notch signaling 
that depends on proper V-ATPase function (Yan et al., 2009; 
Vaccari et al., 2010) and is required to maintain the pool of 
neural progenitors in the developing fly brain (Bowman et 
al., 2008; Egger et al., 2010; Wang et al., 2011). Indeed, Notch 
phenotypes were previously found in ATP6AP2 mutant wing 
clones (Hermle et al., 2013), and more importantly, reduction 
of Notch signaling because of inhibition of the V-ATPase has 
been shown to deplete neural stem cells in mice by promot-
ing their differentiation (Lange et al., 2011).
Interestingly, late-onset cerebral manifestations such as 
Parkinsonism and epilepsy are the main problems in patients 
with exon-skipping mutations in ATP6AP2 (Ramser et al., 
2005; Korvatska et al., 2013). However, these patients do not 
exhibit any obvious liver, immune, or skin defects. Further-
more, we found almost normal glycosylation in one of these 
patients as well as no effect on the interaction with ATP6AP1 
upon deletion of exon 4 (Fig. S2, a–c). These results suggest 
that the clinical manifestation of ATP6AP2 deficiency de-
pends on the severity of the mutations. Indeed, whereas the 
exon-skipping mutations have only partial penetrance reduc-
ing the levels of full-size ATP6AP2 transcripts by <50% (Kor-
vatska et al., 2013), the missense mutations described here 
lead to impaired protein stability and the inability to fully 
rescue the embryonic lethality of the Drosophila null mu-
tation. In particular, we provide evidence that ATP6AP2L98S 
is misfolded in the ER and targeted for ERAD. Thus, it is 
very likely that missense mutations have a stronger impact on 
overall ATP6AP2 function than the exon-skipping mutations.
In summary, we identify three individuals with a new 
glycosylation and autophagy disorder caused by different 
point mutations in the luminal domain of ATP6AP2. Our 
functional studies using cell culture, Drosophila, and mouse 
models suggest that the missense mutations reduce the inter-
action with V0 assembly factors and, consequently, V-ATPase 
activity. Interestingly, the lack of the ER retrieval motif caused 
more cleavage and led to reduced survival, fat accumulation, 
and autophagy defects in Drosophila, suggesting that retro-
grade Golgi-to-ER transport prevents cleavage in the Golgi 
and is required for proper ATP6AP2 function. Moreover, we 
demonstrate that proteolytic processing of ATP6AP2 is tis-
sue-dependent (Fig.  6  e), similar to what has been shown 
before for ATP6AP1 (Jansen et al., 2016a). Our results thus 
provide a better understanding of ATP6AP2 functions and 
pave the way for additional studies on how ATP6AP2 pro-
cessing and trafficking controls V-ATPase assembly.
MAterIAls And MetHods
ethics statement
Research on patients’ cells was prospectively reviewed and 
approved by the Ethical Committee of the University Hospi-
tals of Leuven and Münster.
exome sequencing
For the p.L98S case, mutation identification was achieved 
by whole exome sequencing. Genomic DNA was sheared 
by sonication, platform-specific adaptors were ligated, and 
the resulting fragments were size selected. The library was 
captured using the SeqCap EZ Human Exome Library 
v3.0 (Roche NimbleGen), and paired end (2 × 101 bp) se-
quenced on a HiSeq2000 (Illumina). Reads were aligned to 
the human reference genome (hg19) using BWA (v0.6.2), 
and duplicate reads were removed using Picard MarkDupli-
cates (v1.78). Local realignment around indels, base quality 
score recalibration, and variant calling were performed using 
GATK (v2.4.9) RealignerTargetCreator, IndelRealigner, 
BaseRecalibrator, and UnifiedGenotyper. Variants were an-
notated using Annovar (v11-02-2013). Synonymous variants 
were excluded, whereas variants with a frequency <5% in the 
1000 Genomes project, ESP, GoNL, and our in-house data-
base were further considered. Subsequent prioritization was 
then applied based on recessive inheritance, conservation, and 
pathogenicity prediction scores.
For the p.R71H cases, whole exome analysis of the pa-
tients DNA was done on an Illumina HiSeq2500. Subsequent 
prioritization in both cases was then applied based on recessive 
inheritance, conservation, and pathogenicity prediction scores.
sanger sequencing
Total RNA was isolated from the primary fibroblasts of the 
patient and control cells using the RNeasy kit (QIA GEN). 
2 µg of purified total RNA was subjected to RT with the 
First-Strand cDNA synthesis kit (GE Healthcare) following 
the manufacturer’s instructions. For PCRs, cDNAs obtained 
after RT were diluted 1:5.
Genomic DNA was extracted from white blood cells 
from the patient and controls using the DNeasy Blood & 
Tissue kit (QIA GEN) according to the manufacturer’s pro-
tocol. Primers were designed (Primer Blast) to amplify the 
different exons of the ATP6AP2 gene (available from Gen-
Bank under accession no. NM_005765.2), including at least 
50 bp of the flanking intronic regions. Sequences of the 
primers for exon 3 are as follows: ATP6AP2_E03_F: 5′-ACC 
GCT TTG TGC TTT TCA AT-3′; ATP6AP2_E03_R: 5′-
TCA CCC ACA TTG CCT GAA TA-3′.
DNA of the patients and family members of family 
2 was isolated from EDTA blood using the DNeasy Blood 
& Tissue kit (QIA GEN) according to the manufactur-
er’s protocol. Primer sequences used for Sanger sequencing 
of ATP6AP2 (exon 3) were as follows: ATP6AP2 (exon 3) 
forward: 5′-TTG TCA GTG TCA TCT CAG AAC CCC-3′; 
ATP6AP2 (exon 3) reverse: 5′-TGG CTC TCT TTT TCA 
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AGC CTC TGG-3′. Primers were designed with Primer 
Blast (Ye et al., 2012).
Glycosylation studies
Capillary zone electrophoresis and isoelectric focusing of 
serum transferrin were performed as previously described 
(Zühlsdorf et al., 2015). Glycosylation of serum transferrin was 
additionally assessed via HPLC using the CDT in serum kit 
by Chromesystems according to the manufacturer’s protocol.
For MAL DI-TOF MS analysis, aliquots of 20  µl of 
mouse sera were mixed with lysis buffer (50 mM phosphate 
buffer, pH 7.9, containing 0.5% SDS and 1% β-mercaptoeth-
anol) and incubated at 100°C for 20 min. After cooling and 
the addition of phosphate buffer and 1% Nonidet P-40, three 
units of PNGase F (Roche Diagnostics) were added, and 
samples were incubated for 24 h at 37°C. Released glycans 
were purified on a graphitized carbon column (Alltech). Gly-
cans were permethylated as previously described (Faid et al., 
2007) and purified on an SPE C18 column (Alltech). Per-
methylated glycans were then dissolved in methanol/water 
(1:1 vol/vol) and mixed with an equal volume of dihydroxy-
aminobenzoic acid matrix (Aldrich; 20 mg/ml in methanol/
water 1:1 vol/vol). Mass spectra were acquired using an Ap-
plied Biosystems/MDS Sciex 4800 MAL DI-TOF/TOF an-
alyzer at fixed laser intensity for 1000 shots/spectrum. A total 
of 5000 shots were accumulated in reflectron positive ion 
mode MS for each sample.
Mouse experiments
Generation of the ATP6AP2fl/fl mutant mouse line was de-
scribed previously (Riediger et al., 2011). For in vivo trans-
duction, 109 of adenoviral infectious particles were diluted in 
0.9% NaCl and administered retro-orbitally in a total volume 
of 100 µl per mouse. Mice were sacrificed 10 d after injec-
tion. Adenovirus coding for GFP was used as a control in all 
experiments. GFP and GFP-Cre adenoviral vectors were de-
scribed previously (Nemazanyy et al., 2013). Animals were fed 
a standard chow diet (Teklad global protein diet; 20% protein, 
75% carbohydrate, 5% fat). All mice were sacrificed at 2–4 pm 
in a random-fed state. All animal studies were approved by 
the Direction Départementale des Services Vétérinaires, Pré-
fecture de Police, Paris, France. Liver transaminases ALT and 
AST and total cholesterol levels in serum were determined 
with a multiparametric automate Olympus AU 400.
Plasmids
The cDNAs of Vma21, Atp6ap1, and Atp6ap2 were generated 
by gene synthesis (Invitrogen GeneArt Gene Synthesis ser-
vice) and subcloned using HindIII or NcoI and BamHI sites 
into pFrog-Myc/HA (a pcDNA3-derivative), resulting in C- 
terminal tagged versions of the respective proteins as previ-
ously described (Blanz et al., 2015). A version of ATP6AP2 
lacking exon 4 (101-132aa) was subcloned from the pCS2 vec-
tor (Korvatska et al., 2013) into pFrog-Myc. For the AP-MS 
approach, ATP6AP2 cDNA was subcloned into pDNA4/TO 
with a triple FLAG-tag. All constructs were verified by se-
quencing. To obtain all the mutants of ATP6AP2 with single 
and double amino acid substitutions (ATP6AP2-L98S-HA, 
ATP6AP2-R71H-HA, and ATP6AP2-QxQxx-HA), the 
construct pFrog-ATP6AP2-HA was used as a template, and 
site-direct mutagenesis reactions were performed with the 
QuickChange II Site-Directed Mutagenesis kit (Agilent) ac-
cording to the manufacturer’s instruction using the following 
oligos: -ATP6AP2-L98S-HA: forward: 5′-CCC TTC GGA 
GAA TGC AGT TCC TTT TAG TCT AGA CAGC-3′, reverse: 
5′-CTC CGA AGG GTA GGA GAT GAC GCT GCC TGC-
3′; -ATP6AP2-R71H-HA-forward: 5′-TTC CAC ATG 
CCA CGG GCT ACC ATT ATG GTG ATGG-3′, reverse: 5′-
CCC GTG GAT GGT GGA ATA GGT TAC CCA CGG CAA 
GCCC-3′; -ATP6AP2-QxQxx-HA- (sequential mutagen-
esis): forward: 5′-ATC AGC AGA TTC GAA TAG ATG GAT 
CCT ACC CA-3′, reverse: 5′-AAT CTG CTG ATT TGT CAT 
CCT ATA GAT GAT GC-3′; forward: 5′-GAT TCA AAT AGA 
TGG ATC CTA CCC ATA CGA CG-3′, reverse: 5′-CTA TTT 
GAA TCT GCT GAT TTG TCA TCC TAT AG-3′.
pcDNA3.1-p97-WT-His and pcDNA3.1-p97-QQ-
His were kindly provided by Y. Yihong (National Institute of 
Diabetes and Digestive and Kidney Diseases, National Insti-
tutes of Health, Bethesda, MD).
rnA extraction, rt, and quantitative real-time Pcr
Total RNA was isolated from fibroblasts using a QIA GEN 
RNA extraction kit. cDNA was prepared using reverse tran-
scription iScript cDNA Synthesis kit (Bio-Rad). Relative 
expression levels of ATP6AP2 were determined using the 
Power SYBR Green PCR Master Mix (ThermoFisher) and 
the following primers: ATP6AP2 exon 2 forward, 5′-CTG 
CAT TGT CCA TGG GCT TC-3′, and ATP6AP2 exon 3 re-
verse, 5′-AAC AGG TTA CCC ACT GCG AG-3′. Expression 
levels were normalized to HPRT.
cell culture, Western blotting, and immunoprecipitation
Primary fibroblasts from patients and controls were grown 
from a skin biopsy and cultured in Nutrient Mixture F-12 
DMEM/F-12 (ThermoFisher) supplemented with 10% FBS 
at 37°C under 5% CO2. Research on patients’ cells was pro-
spectively reviewed and approved by the Ethical Committees 
of the University Hospital of Leuven and Münster. HEK293T 
cells were routinely grown at 37°C in DMEM (ThermoFisher) 
containing 10% FBS. HEK293 STT3A KO, STT3B KO, and 
the parental HEK293 cells were cultured as described previ-
ously (Cherepanova and Gilmore, 2016). Cells were transfected 
by using Lipofectamine 2000 (Invitrogen) in Opti-MEM 
(ThermoFisher) according to the manufacturers’ instructions.
The expression of ATP6AP2 forms was analyzed by 
Western blotting 48 h after transfection. For this, cells were 
harvested in 50 µl of lysis buffer (1% Triton X-100 in PBS) 
supplemented with protease inhibitor cocktail (Roche). After 
30-min incubation in lysis buffer at 4°C, the lysates were then 
cleared by centrifugation for 10 min at 13,200 rpm at 4°C. 
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The protein concentration was determined using a Pierce 
BCA Protein Assay kit (Thermo Scientific). For each exper-
iment, aliquots of the lysate (20 µg total protein per aliquot) 
were denatured using 1× SDS sample buffer for 25 min at 
55°C and analyzed by SDS-PAGE. For immunoblotting, pro-
teins were transferred to nitrocellulose filters by using the 
iBlot2 Dry Blotting system (ThermoFisher) and then blocked 
for 1 h in blocking buffer (5% nonfat dry milk, 0.2% Tween-
20 in PBS). The membranes were incubated overnight with 
the specific primaries antibodies, followed by HPR-conju-
gated secondary antibodies. To assess relative protein levels, 
band intensity was measured with the ImageJ software.
For the coIP (anti-Myc), HEK293T cells were transfected 
with 1 µg of ATP6AP2WT-HA, 1 µg of ATP6AP2L98S-HA, and 
1 µg of ATP6AP2R71H-HA. For the reciprocal coIP (anti-HA), 
cells were transfected with 1 µg of ATP6AP2WT-HA, 2 µg of 
ATP6AP2L98S-HA, and 2 µg of ATP6AP2R71H-HA. Cells were 
harvested in 100 µl of EBC lysis buffer (120 mM NaCl, 50 mM 
Tris [pH 8.0], 5 mM EDTA, 50 mM Hepes, and 0,5% NP-40) 
supplemented with protease inhibitor. After 1 h incubation in 
lysis buffer at 4°C, the lysates were then centrifuged for 10 
min at 13,200 rpm at 4°C, and the protein concentration was 
determined as before. For each sample, 2 mg of protein was in-
cubated overnight with 1 µg of mouse mAb anti-Myc at 4°C. 
Next, 50 µl of Dynabeads Protein G (Thermo Scientific) was 
added 1 h at 4°C and washed according to the manufacturer’s 
instructions. The immunoprecipitated proteins were eluted by 
addition of 30 µl of 4× SDS sample buffer, followed by 5 min 
incubation at 95°C. Initial lysates and immunoprecipitated 
proteins were analyzed by SDS-PAGE and immunoblotted 
with specific antibodies. For the endogenous immunoprecip-
itation, 2 mg of lysates were incubated overnight with either 
rabbit Ig (as control) or with 2 µg of rabbit polyclonal antibody 
anti-ATP6AP2 at 4°C. 100 µl of Dynabeads Protein G was 
added, and the proteins were eluted and analyzed by Western 
blotting as described in the previous paragraph.
The following antibodies were used: rabbit polyclonal 
anti-Myc antibody (sc-789) and mouse monoclonal anti-Myc 
antibody (sc-40) both from Santa Cruz Biotechnology, rat 
monoclonal anti-HA antibody (11867423001; Roche), rab-
bit polyclonal anti-ATP6AP1 antibody (ab176609; Abcam), 
and rabbit polyclonal anti-ATP6AP2 antibody (HPA003156), 
mouse monoclonal anti–β-actin antibody (A1978), and 
mouse monoclonal antihistidine antibody (H1029), all from 
Sigma-Aldrich. Secondary antibodies used were antirat, 
antirabbit, and antimouse Horseradish Peroxidase Conju-
gated (Thermo Scientific).
Indirect immunofluorescence studies
HeLa cells were grown on glass coverslips in DMEM (Ther-
moFisher) supplemented with 10% FBS. Cells were trans-
fected with Lipofectamine 2000 (Invitrogen) in Opti-MEM 
(ThermoFisher) according to the manufacturer’s instructions. 
The localization of ATP6AP2 construct was analyzed 48 h 
after transfection. For this, cells were fixed with 4% formal-
dehyde in PBS for 30 min at room temperature. Formalde-
hyde was quenched with 0.1 M glycine in PBS for 5 min on 
ice, and cells were made permeable with 0.1% Triton X-100 
in PBS 10 min at room temperature. Cells were blocked for 
30 min at room temperature in BSA 3% and labeled with 
the appropriate primary antibodies overnight at 4°C in 0.1% 
PBS–Tween-20 supplemented with 3% BSA. After washing, 
cells were incubated 1 h at room temperature with second-
ary antibodies (dilution 1:200) and Hoechst (0.5 µg ml−1) in 
PBS. Coverslips were mounted in Moviol. Primary antibodies 
used were rat anti-HA (11867423001; Roche), mouse anti- 
Calnexin (ALX-804-014-R100; Enzo Life Science), and rab-
bit anti-Giantin (Antibody platform Institut Curie). Second-
ary antibodies used were fluorescent conjugated Alexa Fluor 
488 and Alexa Fluor 555 (Invitrogen Molecular Probes).
Analysis of protein stability and 
glycosidase inhibitor treatments
For the cycloheximide chase assay, 30, 42, 45, and 46 h after 
transfection, culture medium was changed for the chase 
medium (DMEM supplemented with 20 mM Hepes), and 
cycloheximide (Sigma-Aldrich) was added to reach a final 
concentration of 100  µM. Vehicle controls were treated 
with DMSO for 18 h.
For the deglycosylation digestion, 20 µg of cell lysates 
were treated according to the manufacturer's instructions and 
incubated for 1 h at 37°C with 500 U of Endo H, 500 U of 
PNGase F, 40,000 U of O-glycosidase (New England Bio-
Labs), or 0.005 U Sialidase A (Prozyme).
Proteomics
Transfection of HEK293 cells and AP-MS were performed 
as previously described (Jäger et al., 2011). In brief, pools 
of HEK293 cells transiently expressing ATP6AP2-3×FLAG 
were used to precipitate ATP6AP2 and associated protein 
complexes using affinity gels followed by MS analysis. Bio-
logical triplicates of ATP6AP2-3xFLAG were performed, 
and only those proteins that were detected in all spectral 
counts are shown. Data were analyzed with two AP-MS 
scoring algorithms, MiST (Jäger et al., 2011) and Comp-
PASS (Sowa et al., 2009).
Y2H analysis
The Y2H screen was performed by Hybrigenics Services. 
The coding sequence of the human ATP6AP2 wt NT17-275 
was PCR-amplified and cloned into pB27 as a N-terminal 
fusion to bait fragment (LexA-ATP6AP2 wt NT17-275). The 
constructs were checked by sequencing and used as a bait to 
screen a random-primed mouse kidney cDNA library con-
structed into pP6. pB27 and pP6 derive from the original 
pBTM116 (Vojtek and Hollenberg, 1995) and pGAD GH 
(Bartel et al., 1993) plasmids, respectively. ULTImate Y2H 
screening was performed against the mouse kidney cDNA 
library using ATP6AP2 wt NT17-275 as a bait. The prey frag-
ments cloned in frame with the Gal4 activation domain into 
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plasmid pP6, derived from the original pGAD GH (Bartel et 
al., 1993), were checked by sequencing.
For 1-by-1 screening, the prey fragment for the human 
ATP6AP1 (ATP6AP1-NT30-254, PCR amplified from the 
coding sequence of the human ATP6AP1-NT30-254), human 
ATP6AP2L98SNT17-275 (PCR amplified), and human ATP6A-
P2R71HNT17-275 (fragment synthesized) were cloned in frame 
with the LexA DNA binding domain into pB27 (LexA-AT-
P6AP1-NT30-254 and LexA-ATP6AP2L98SNT17-275). The 
prey fragments for the human ATP6AP2 wt NT17-275, the 
human ATP6AP2L98SNT17-275, and the ATP6AP2R71HNT17-275 
were cloned in frame with the Gal4 AD into plasmid pP7 
(AD-ATP6AP2 wt NT17-275, AD-ATP6AP2L98SNT17-275, and 
AD-ATP6AP2R71HNT17-275). pP7 derives from the original 
pGAD GH (Bartel et al., 1993). The pP7 prey plasmid used 
in the control assay is derived from the pP6 plasmid. All con-
structs were checked by sequencing the entire inserts.
Fly strains and husbandry
Drosophila melanogaster stocks were raised on standard corn-
meal food at 25°C. The following stocks were used: w1118 
(used as WT control), FRT82B, ATP6AP2Δ1, ATP6AP2>AT-
P6AP2WT-Myc, ATP6AP2>ATP6AP2WT, and ATP6AP2>AT-
P6AP2AxxA, which have all been described in (Hermle et al., 
2013), ATP6AP2>ATP6AP2L98S, ATP6AP2>ATP6AP2ΔKKxx, 
and UAS>ATP6AP2L98S were generated in this study (see 
next paragraph), tub-GFP–LAMP (gift from H. Krämer, UT 
Southwestern Medical Center, Dallas, TX), hs-Flp; tub-FRT-
Gal80-FRT-Gal4, UAS–mCD8–mRFP (gift from F. Bosveld, 
Institut Curie, Paris, France), hs-Flp; UAS-Dcr2; R4-mCher-
ry-Atg8, Actin-FRT-CD2-FRT-Gal4,UAS-GFPnls/TM6B 
(gift from G. Juhasz, Eotvos Lorand University, Budapest, 
Hungary), UAS-ATP6AP2RNAi, GD5830, UAS-ATP6V1C1RNAi, 
KK101527, UAS-ATP6AP1RNAi, GD48017 (all from VDRC Stock 
Center), FRT42D, ubi-mRFPnls (Bloomington Stock Cen-
ter), hs-Flp;; Tub-FRT-Gal80-FRT-Gal4, UAS-mCD8-RFP 
(gift from F. Bosveld), and Gal4 drivers ptc-Gal4 and ap-Gal4 
(Bloomington Stock Center). For the precise genotype used 
in each figure, see also Table S1.
ATP6AP2>ATP6AP2L98S-, ATP6AP2>ATP6AP2ΔKKxx-, 
and UAS>ATP6AP2L98S-expressing transgenic flies have been 
created by site-directed mutagenesis using the QuickChange 
II Site directed Mutagenesis kit (Agilent) according to the 
manufacturer’s instructions. For ATP6AP2>ATP6AP2L98S 
and ATP6AP2>ATP6AP2ΔKKxx, mutagenesis was performed 
on the pattB plasmid containing the WT extended gene re-
gion of ATP6AP2 (Hermle et al., 2013) using the following 
oligos: -ATP6AP2L98S-: forward: 5′-CGT TCC GGA GCC 
TGT CGA CTC GTA GGT CTT GACG-3′, reverse: 5′-CGT 
TCC GGA GCC TGT CGA CTC GTA GGT CTT GACG-3′; 
-ATP6AP2ΔKKxx-: forward: 5′-CCT TAG TTG TCC TTC 
TAG ATG CGG GTA GAG GTC-3′, reverse: 5′-GAC CTC 
TAC CCG CAT CTA GAA GGA CAA CTA AGG-3′.
For UAS>ATP6AP2L98S, mutagenesis was done on the 
pUASg-HAattB plasmid containing the coding sequence of 
ATP6AP2 optimised by GeneArt (Invitrogen) with a final 
stop codon that impedes the expression of the HA tag, using 
the following primers: forward: 5′-CGT GAA GAC CTA CGA 
GTC GAC CGG CAG CGG CACC-3′, reverse: 5′-GGT GCC 
GCT GCC GGT CGA CTC GTA GGT CTT CACG-3′.
All constructs were injected into flies with the attP 
landing site at 86FB by Bestgene.
Clones were generated using FLP/FRT or flip-out 
techniques (Xu and Rubin, 1993). Clones in fat bodies 
were induced in embryos by 2  h heat shock at 37°C (ex-
cept for clones generated with the hs-Flp, UAS-Dcr2;Actin> 
CD2>Gal4;UAS-GFP,R4-mCherry-Atg8a/TM6B stock, 
which form spontaneous clones without heat shock) and an-
alyzed 4 d later in wandering third instar larvae.
Percentage of pupariation and eclosion
50–100 third instar larvae of each genotype were collected 90 
± 4 h after egg laying on standard food plates supplemented 
with dried yeast (2–3 h egg collections) and reared on tubes 
containing standard food at 25°C. The number of larvae that 
underwent pupariation was scored twice a day. Pupae were 
then left to eclose, and the number of surviving adult flies 
was scored. Five independent experiments were performed 
with genotypes WT, ATP6AP2WT-Myc, ATP6AP2WT, and 
ATP6AP2L98S. ATP6AP2ΔKKxx and ATP6AP2AxxA were scored 
in three independent experiments.
Western blotting of drosophila extracts
For whole larval extracts, five wandering third instar larvae 
per genotype were collected and washed once in PBS, etha-
nol 70%, and water to remove food, surface bacteria, and other 
contaminants. Larvae were transferred to an Eppendorf tube 
containing 100 µl of lysis buffer (50 mM Tris-base, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with 
protease and phosphatase inhibitors cocktails (Roche) and 
homogenized three times with a pellet pestle for 10–15 s on 
ice. For fat body and brain extracts, for preparation of lysates 
from third instar fat bodies and larval brains, whole fat bod-
ies from 15 larvae per genotype and 50 brains per genotype 
were dissected in PBS, transferred to Eppendorf tubes con-
taining 50 µl of lysis buffer, incubated for 15 min on ice, and 
lysed by sonication. Lysates were cleared by centrifugation at 
maximum speed for 10 min, and the supernatants were trans-
ferred to clean Eppendorf tubes. Protein concentration was 
determined using the Pierce BCA Protein Assay kit (Thermo 
Scientific) according to the manufacturer’s instructions. Sam-
ples (20 µg) were analyzed by SDS-PAGE followed by im-
munoblotting. The following antibodies were used: guinea 
pig anti-ATP6AP2 (Hermle et al., 2013), mouse anti–β- 
actin antibody (Sigma-Aldrich, A1978), mouse anti–α-tubu-
lin (Sigma-Aldrich, T6199), rabbit anti-Ref(2)P (gift from 
T.E. Rusten), rabbit anti–p4E-BP (Cell Signaling, 2855) and 
rabbit anti-Atg8a (gift from G. Juhasz). Secondary antibod-
ies used were anti–guinea pig, anti–rabbit, and anti–mouse 
Horseradish Peroxidase Conjugated (Thermo Scientific).
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staging, starvation, and refeeding of larvae
0-2 h egg collections were done at 25°C using egg collection 
chambers on 60-mm petri dishes containing standard food 
supplemented with dry yeast. 72 h after larval hatching, 50 
larvae (mid third instar) were transferred to vials containing a 
filter paper soaked in PBS and kept at 25°C for 6 h (starva-
tion). Subsequently, half of the starved larvae were transferred 
to dishes containing yeast paste and kept at 25°C for 30 min 
(refeeding). Fat bodies from fed, starved, and refed larvae were 
dissected and processed as before for Western blotting analyses.
Immunohistochemistry
Brains and fat bodies from third instar larvae were dissected 
in PBS, fixed for 20 min (30 min in the case of p4E-BP stain-
ing) in 4% paraformaldehyde in PBS (+0.1% Triton X-100 
for brains), washed three times in PBS-T (PBS + 0.3% Tri-
ton X-100 for brains and PBS + 0.1% Triton X-100 for 
fat bodies), and incubated overnight at 4°C with primary 
antibodies diluted in PBS-T. After washing, tissues were in-
cubated overnight at 4°C for brains and 2 h at room tem-
perature for fat bodies with secondary antibodies (dilution 
1:200) and Hoechst (0.5 µg ml−1) diluted in PBS-T. Tissues 
were washed twice in PBS-T followed by a wash in PBS. 
Tissues were mounted in mounting medium (1.25% n-pro-
pyl gallate, 75% glycerol, 25% H2O). Primary antibodies 
used were rabbit anti-Dpn (1:200, gift from R. Basto), rab-
bit anti-GFP (1:500, Antibody Platform Institut Curie), rat 
anti-RFP (1:200, 5F8, ChromoTek), rabbit anti-mCherry 
(1:100, Clontech), rat anti-ELAV (1:100, 7E8A10, Devel-
opmental Studies Hybridoma Bank), guinea-pig anti-AT-
P6AP2 (Hermle et al., 2013), rabbit anti-Ref(2)P (gift from 
T.E. Rusten), rabbit anti-Atg8a (gift from G. Juhasz) and 
rabbit anti–p4E-BP (2855, Cell Signaling). Secondary an-
tibodies used were fluorescent conjugated Alexa Fluor 488, 
Alexa Fluor 555, Alexa Fluor 633, and Alexa Fluor 647 (In-
vitrogen Molecular Probes).
Bodipy and lysotracker staining
For Bodipy labeling, dissected fat bodies were fixed for 30 
min in 4% paraformaldehyde in PBS, washed in PBS, and 
incubated with BOD IPY 493/503 (2.5 µg ml−1, Molecu-
lar Probes) and Hoechst (0.5 µg ml−1) diluted in PBS for 
30 min. Tissues were mounted as described in the Immu-
nohistochemistry section.
For Lysotracker labeling, dissected fat bodies were in-
cubated with LysoTracker Green DND-26 (100 nM, Mo-
lecular Probes) and Hoechst (0.5 µg ml−1) diluted in PBS 
for 3 min, washed in PBS, and fixed in 4% paraformaldehyde 
in PBS for 10 min. Fat bodies were washed three times in 
PBS and mounted as before.
tissue imaging
All images were acquired on a Leica TCS SP8 equipped 
with a 405-nm laser line and a White Light Laser with a 
63x/1.4 DIC Lambda blue PLAN APO CHR OMA TE ob-
jective. Images were processed with Fiji (Schindelin et al., 
2012) and Adobe Photoshop.
tAG assay
Five wandering third instar larvae per genotype were collected 
and washed once in PBS, ethanol 70%, and water to remove 
food, surface bacteria, and other contaminants. Larvae were 
transferred to an Eppendorf tube containing 200 µl of PBS-T 
(PBS+0.05% Triton X-100 supplemented with protease in-
hibitors, Roche) and homogenized three times with a pellet 
pestle for 10–15  s on ice. Homogenates were subsequently 
sonicated. 10  µl of homogenized sample was collected for 
protein determination, and the rest of the homogenate was 
incubated at 70°C for 10 min. 20 µl of the sample and also 
standards were added to tubes containing 20 µl PBS-T + PI 
(baseline) or 20 µl TAG reagent (Sigma T2449) and incubated 
for 30 min at 37°C. Samples were centrifuged at maximum 
speed for 3 min, and 7.5 µl of each sample supernatant was 
transferred to clear-bottom 96-well plate containing 22.5 µl 
of PBS-T. 100 µl of free glycerol reagent (Sigma F6428) was 
added, and the mix was incubated at 37°C for 5 min. Absor-
bance was measured in a spectrophotometer at 560 nm. TAG 
concentration for each sample was determined by subtracting 
the absorbance for the free glycerol in the untreated samples 
(baseline) from the total glycerol concentration in samples that 
were incubated in triglyceride reagent. As a final step, samples 
were normalized to the corresponding protein concentrations.
electron microscopy
Drosophila prepupal wings (5.5 h APF) were dissected and 
directly fixed with 4% paraformaldehyde and 1% glutaralde-
hyde in 0.1 M PB overnight at 4°C. After fixation, wings were 
washed in PB, treated with 2% OsO4, stained with uranyl ac-
etate, dehydrated, and embedded in epoxy resin (Durcupan 
ACM, Fluka, Sigma-Aldrich). 40 nm ultrathin cross sections 
in the proximal-distal axis were cut using an ultramicrotome 
(Leica UC6) and analyzed with a Zeiss LEO 906 transmission 
electron microscope operated at 80 kV and equipped with a 
2K CCD camera (Tröndle).
online supplemental material
Fig. S1 shows the glycosylation diagnostics for patients P2 and 
P3. Fig. S2 shows the glycosylation diagnostics of the patient 
with the exon-skipping mutation (P4) and the normal inter-
action of ATP6AP2 Δexon4 with ATP6AP1. Fig. S3 shows 
the characterization of ATP6AP2 cKO mice. Fig. S4 shows 
the subcellular localization of the different ATP6AP2 con-
structs in HeLa cells. Fig. S5 shows the interaction between 
ATP6AP2 and ATP6AP1 using the Y2H method. Table S1 
shows the Drosophila genotypes used in this study.
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